Document is current
Any future updates will be listed below
-
Authors
Hwu, Paul Wuh‐Liang https://orcid.org/0000-0001-6690-4879
Kiening, Karl
Anselm, Irina https://orcid.org/0000-0003-2089-0699
Compton, David R https://orcid.org/0000-0001-9669-1616
Nakajima, Takeshi
Opladen, Thomas https://orcid.org/0000-0003-4349-7662
Pearl, Phillip L https://orcid.org/0000-0002-6373-1068
Roubertie, Agathe https://orcid.org/0000-0002-8180-4857
Roujeau, Thomas
Muramatsu, Shin‐ichi https://orcid.org/0000-0002-3185-7790
- License Information
-
More Information
Article History
Received: 15 June 2021
Revised: 9 July 2021
Accepted: 27 July 2021
First Online: 23 August 2021
Conflict of interest
: WLH participated as an advisory board member, received consulting fees, and was a speaker for PTC Therapeutics, BioMarin, and Sanofi; was a grant recipient for PTC Therapeutics and BioMarin; and was research investigator for PTC Therapeutics. SM owns stock in Gene Therapy Research Institution; he participated as an advisor board member, received consulting fees, and was a speaker for PTC Therapeutics. DC is an employee, research investigator, and stock owner for PTC Therapeutics. PP has received consulting fees from PTC Therapeutics and Origin Biotherapeutics. TO was a grant recipient of Dietmar‐Hopp‐Foundation and a speaker for PTC Therapeutics. TR and KK have received consulting fees for PTC Therapeutics. AR has received consulting fees from PTC Therapeutics and GW Pharmaceuticals. IA and TN have no relevant relationships to disclose.
